During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, scientists from leading preclinical contract organizations (CROs) discussed how traditional IND-enabling studies involving primates and dogs can be complemented (and sometimes even replaced) by alternative models such as mice, rats, rabbits and pigs.
Dr. Dany Salvail (IPST, QC, Canada) explained how experienced pharmacologists rely on alternate models combined with sophisticated measurement techniques that go well beyond the ICH guidelines to help sponsors truly understand and quantify liabilities associated with their lead compounds early on.
IIPS’s flexible approach allows their scientists to rapidly adapt study designs and, if needed, conduct complementary safety and efficacy assays at minimal additional cost to better characterize physiological effects of compounds.
This article summarizes some of the key points that were presented during the event and includes the video recording of the talk.
Dan Salvail completed his undergraduate training in Biochemistry at Bishop’s University, in Canada, before being granted a Ph.D in Thoracic Physiology & Biophysics at the University of Sherbrooke.
While pursuing post-graduate training in cardiology, he co-founded IPS Therapeutique Inc., a CRO specialized in preclinical cardiovascular efficacy and safety assessment, in which he still holds a management role. As Director of Pharmacology and then Vice-President, he has assembled preclinical drug development, and safety testing strategies for dozens of compounds, and overseen testing for 3 000 + drug candidates over the last 24 years.
The experience gained with dozens of classes of compounds and the central role played in the development of highly successful drugs led to international recognition, presentations given in North America, Europe, Asia, and subsequent requests to act as a consultant in preclinical cardiology.
To complement the service offer from IPS Therapeutique Inc., he co-founded ToxiPharm Laboratories Inc., a hybrid CRO-expert consultation group which relied on academic and industry experts to develop customized preclinical solutions for unique applications, models, and molecules. His involvement with ToxiPharm provided a framework for more consultant work, focusing on the efficacy and safety assessment of promising drug candidates targeting non-cardiac diseases.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.